Open access
2,364
Views
4
CrossRef citations to date
0
Altmetric
Diabetes
Efficacy and safety of ertugliflozin across racial groups in patients with type 2 diabetes mellitus
Jie LiuMerck & Co. Inc., Kenilworth, NJ, USA;
, Lisa TarasenkoPfizer Inc., New York, NY, USA;
, Annpey PongMerck & Co. Inc., Kenilworth, NJ, USA;
, Susan HuyckMerck & Co. Inc., Kenilworth, NJ, USA;
, Larry WuMerck & Co. Inc., Kenilworth, NJ, USA;
, Shrita PatelMerck & Co. Inc., Kenilworth, NJ, USA;
, Anne HickmanPfizer Inc., Groton, CT, USA;
, James P. MancusoPfizer Inc., Groton, CT, USA;
, Ira GantzMerck & Co. Inc., Kenilworth, NJ, USA;
& Steven G. TerraPfizer Inc., Andover, MA, USACorrespondence[email protected]
http://orcid.org/0000-0002-5815-6193
Pages 1277-1284
|
Received 01 Nov 2019, Accepted 23 Mar 2020, Published online: 13 May 2020
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.